Adaptimmune Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	65.09	178.03	60.28	27.15	6.15	3.96
Revenue Growth (YoY)	-53.99%	195.34%	122.05%	341.50%	55.36%	252.76%
Cost of Revenue	128.69	149.13	126.51	127.73	111.09	91.57
Gross Profit	-63.61	28.9	-66.23	-100.58	-104.94	-87.61
Selling, General & Admin	84.26	81.31	64.46	63.39	57.31	45.8
Operating Expenses	84.26	81.31	64.46	63.39	57.31	45.8
Operating Income	-147.87	-52.41	-130.69	-163.97	-162.25	-133.41
Interest Expense	-5.67	-3.35	-	-	-	-
Interest & Investment Income	5.02	6.6	5.96	1.54	1.1	2.31
Currency Exchange Gain (Loss)	-1.18	-1.73	-0.81	-0.54	3.85	1.11
Other Non Operating Income (Expenses)	-	-	-	-	-0.01	-0.03
EBT Excluding Unusual Items	-149.69	-50.89	-125.54	-162.96	-157.31	-130.02
Merger & Restructuring Charges	-5.95	-5.95	-9.05	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	0.01	0.09
Asset Writedown	-10.4	-10.4	-	-	-	-
Other Unusual Items	-	-	22.05	-	-	-
Pretax Income	-166.05	-67.24	-112.54	-162.96	-157.3	-129.93
Income Tax Expense	3.71	3.58	1.34	2.5	0.79	0.16
Net Income	-169.76	-70.81	-113.87	-165.46	-158.09	-130.09
Net Income to Common	-169.76	-70.81	-113.87	-165.46	-158.09	-130.09
Shares Outstanding (Basic)	258	252	201	161	156	142
Shares Outstanding (Diluted)	258	252	201	161	156	142
Shares Change (YoY)	8.53%	25.48%	24.73%	3.47%	9.37%	35.72%
EPS (Basic)	-0.66	-0.28	-0.57	-1.03	-1.01	-0.91
EPS (Diluted)	-0.66	-0.30	-0.57	-1.03	-1.02	-0.91
Free Cash Flow	-191.67	-74.09	-145.56	-171.27	2.16	-55.93
Free Cash Flow Per Share	-0.74	-0.29	-0.72	-1.06	0.01	-0.39
Gross Margin	-97.73%	16.23%	-109.86%	-	-	-
Operating Margin	-227.19%	-29.44%	-216.81%	-603.97%	-2638.58%	-3370.52%
Profit Margin	-260.82%	-39.78%	-188.90%	-609.46%	-2570.99%	-3286.81%
Free Cash Flow Margin	-294.49%	-41.62%	-241.47%	-630.86%	35.05%	-1413.14%
EBITDA	-137.24	-41.18	-120.85	-157.89	-155.68	-125.81
EBITDA Margin	-210.86%	-23.13%	-200.48%	-	-	-
D&A For EBITDA	10.63	11.23	9.84	6.08	6.57	7.59
EBIT	-147.87	-52.41	-130.69	-163.97	-162.25	-133.41
EBIT Margin	-227.19%	-29.44%	-216.81%	-	-	-
Revenue as Reported	65.09	178.03	60.28	27.15	6.15	3.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.